Corbus Pharmaceuticals Holdings Investor Relations Material

Corbus Pharmaceuticals Holdings Inc. is a biopharmaceutical company that specializes in precision oncology. The company's research and development efforts focus on innovative treatments that target well-understood biological pathways related to cancer. Corbus' pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) designed to target the Nectin-4 protein on cancer cells, and CRB-601, an anti-integrin monoclonal antibody that inhibits the activation of TGFβ on cancer cells. These treatments are intended to combat serious illnesses by offering new therapeutic options for patients. The company is headquartered in Norwood, Massachusetts, and its shares are listed on the NASDAQ.